Press Release Archives | Page 3 of 4 | CereVasc | Neurological Disease Device Company

28 Mar, 2023

CereVasc Appoints Dr. Adel Malek Chief Medical Officer

Admin2023-11-06T22:03:27+00:00March 28th, 2023|

21 Nov, 2022

Tufts Medical Center Neurosurgeons and CereVasc Co-founders Honored by the Society of Vascular and Interventional Neurology for Innovation in Hydrocephalus Treatment

Admin2023-11-06T21:59:07+00:00November 21st, 2022|

29 Aug, 2022

CereVasc Announces First Patient Treated in U.S. Pilot Trial Evaluating the eShunt System in Patients with Normal Pressure Hydrocephalus

Admin2023-11-06T21:52:45+00:00August 29th, 2022|

09 Aug, 2022

CereVasc Announces FDA Approval of Second IDE Study of the eShunt® System

Admin2023-11-06T21:48:30+00:00August 9th, 2022|

25 Apr, 2022

First patient treated in CereVasc® clinical trial of eShunt® System for Normal Pressure Hydrocephalus

Admin2023-11-06T21:37:10+00:00April 25th, 2022|

08 Feb, 2022

CereVasc Receives FDA IDE Approval to Begin Initial Clinical Study of the eShunt® System for Patients with Normal Pressure Hydrocephalus

Admin2023-11-06T21:21:09+00:00February 8th, 2022|

07 Dec, 2021

CereVasc Announces Publication of First-in-Human Case Report of its eShunt System for the Treatment of Communicating Hydrocephalus

Admin2023-11-06T21:13:31+00:00December 7th, 2021|

10 Feb, 2021

First patient treated in CereVasc clinical trial of eShunt™ System for communicating hydrocephalus

cerevasc2023-02-14T15:48:38+00:00February 10th, 2021|

04 Nov, 2019

CereVasc, LLC Receives Approval to Initiate First-in-Human Clinical Study of the eShunt System

cerevasc2023-02-14T15:48:39+00:00November 4th, 2019|

25 Sep, 2017

Initial Results of the eShunt System Presented at the International Society of Hydrocephalus and Cerebrospinal Fluid Disorders Annual meeting in Kobe, Japan

cerevasc2023-02-14T15:48:40+00:00September 25th, 2017|